185 related articles for article (PubMed ID: 33813646)
1. Comparison of HBV reactivation between patients with high HBV-DNA and low HBV-DNA loads undergoing PD-1 inhibitor and concurrent antiviral prophylaxis.
He MK; Peng C; Zhao Y; Liang RB; Lai ZC; Kan A; Li QJ; Wei W; Zhang YJ; Chen MS; Guo RP; Shi M
Cancer Immunol Immunother; 2021 Nov; 70(11):3207-3216. PubMed ID: 33813646
[TBL] [Abstract][Full Text] [Related]
2. Comparison of hepatitis B virus reactivation in hepatocellular carcinoma patients who received tyrosine kinase inhibitor alone or together with programmed cell death protein-1 inhibitors.
Lei J; Yan T; Zhang L; Chen B; Cheng J; Gao X; Liu Z; Li Y; Zuo S; Lu Y
Hepatol Int; 2023 Apr; 17(2):281-290. PubMed ID: 36580258
[TBL] [Abstract][Full Text] [Related]
3. Interaction between baseline HBV loads and the prognosis of patients with HCC receiving anti-PD-1 in combination with antiangiogenic therapy undergoing concurrent TAF prophylaxis.
Hu X; Li R; Li Q; Zang M; Yuan G; Chen J
BMC Infect Dis; 2022 Jul; 22(1):614. PubMed ID: 35836207
[TBL] [Abstract][Full Text] [Related]
4. Perioperative reactivation of hepatitis B virus replication in patients undergoing partial hepatectomy for hepatocellular carcinoma.
Huang L; Li J; Lau WY; Yan J; Zhou F; Liu C; Zhang X; Shen J; Wu M; Yan Y
J Gastroenterol Hepatol; 2012 Jan; 27(1):158-64. PubMed ID: 21871026
[TBL] [Abstract][Full Text] [Related]
5. Effects of antiviral therapy on post-hepatectomy HBV reactivation and liver function in HBV DNA-negative patients with HBV-related hepatocellular carcinoma.
Gong WF; Zhong JH; Lu SD; Wang XB; Zhang QM; Ma L; Zhang ZM; Xiang BD; Li LQ
Oncotarget; 2017 Feb; 8(9):15047-15056. PubMed ID: 28122361
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition.
Zhang X; Zhou Y; Chen C; Fang W; Cai X; Zhang X; Zhao M; Zhang B; Jiang W; Lin Z; Ma Y; Yang Y; Huang Y; Zhao H; Xu R; Hong S; Zhang L
J Immunother Cancer; 2019 Nov; 7(1):322. PubMed ID: 31753012
[TBL] [Abstract][Full Text] [Related]
7. Posthepatectomy HBV reactivation in hepatitis B-related hepatocellular carcinoma influences postoperative survival in patients with preoperative low HBV-DNA levels.
Huang G; Lai EC; Lau WY; Zhou WP; Shen F; Pan ZY; Fu SY; Wu MC
Ann Surg; 2013 Mar; 257(3):490-505. PubMed ID: 22868358
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia Lymphoma Study Group.
Kim SJ; Hsu C; Song YQ; Tay K; Hong XN; Cao J; Kim JS; Eom HS; Lee JH; Zhu J; Chang KM; Reksodiputro AH; Tan D; Goh YT; Lee J; Intragumtornchai T; Chng WJ; Cheng AL; Lim ST; Suh C; Kwong YL; Kim WS
Eur J Cancer; 2013 Nov; 49(16):3486-96. PubMed ID: 23910494
[TBL] [Abstract][Full Text] [Related]
9. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy.
Lan JL; Chen YM; Hsieh TY; Chen YH; Hsieh CW; Chen DY; Yang SS
Ann Rheum Dis; 2011 Oct; 70(10):1719-25. PubMed ID: 21719446
[TBL] [Abstract][Full Text] [Related]
10. Effects of antiviral therapy on hepatitis B virus reactivation and liver function after resection or chemoembolization for hepatocellular carcinoma.
Lao XM; Luo G; Ye LT; Luo C; Shi M; Wang D; Guo R; Chen M; Li S; Lin X; Yuan Y
Liver Int; 2013 Apr; 33(4):595-604. PubMed ID: 23402625
[TBL] [Abstract][Full Text] [Related]
11. High titers of anti-HBs prevent rituximab-related viral reactivation in resolved hepatitis B patient with non-Hodgkin's lymphoma.
Cho Y; Yu SJ; Cho EJ; Lee JH; Kim TM; Heo DS; Kim YJ; Yoon JH
J Med Virol; 2016 Jun; 88(6):1010-7. PubMed ID: 26531242
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive outcomes of on- and off-antiviral prophylaxis in hepatitis B patients undergoing cancer chemotherapy: A competing risks analysis.
An J; Shim JH; Kim SO; Choi J; Kim SW; Lee D; Kim KM; Lim YS; Lee HC; Chung YH; Lee YS; Suh DJ
J Med Virol; 2016 Sep; 88(9):1576-86. PubMed ID: 26945543
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Prophylactic Entecavir for Hepatitis B Virus-Related Hepatocellular Carcinoma Receiving Transcatheter Arterial Chemoembolization.
Li X; Zhong X; Chen ZH; Wang TT; Ma XK; Xing YF; Wu DH; Dong M; Chen J; Ruan DY; Lin ZX; Wen JY; Wei L; Wu XY; Lin Q
Asian Pac J Cancer Prev; 2015; 16(18):8665-70. PubMed ID: 26745134
[TBL] [Abstract][Full Text] [Related]
14. Discontinuation of antiviral prophylaxis increased the risk of hepatitis B virus reactivation in glomerulonephritis patients under immunotherapy: a real-life observation.
Fang J; Li W; Tan M; Chen W; Zhang C; Wang W; Xu Q; Guo X
Int Urol Nephrol; 2018 Sep; 50(9):1653-1660. PubMed ID: 29644524
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis B virus reactivation in patients with hepatocellular carcinoma undergoing anti-cancer therapy.
Jang JW
World J Gastroenterol; 2014 Jun; 20(24):7675-85. PubMed ID: 24976705
[TBL] [Abstract][Full Text] [Related]
16. Association of hepatitis B virus DNA levels with efficacy and safety outcomes in patients with hepatitis B virus-associated advanced hepatocellular carcinoma receiving tyrosine kinase inhibitor plus anti-PD-1 antibody: a multicenter propensity-matched study.
Chen QJ; Lin KY; Lin ZW; Zhang B; Liu MQ; Zhang JX; Huang QZ; Lin KC; Zhang JY; Wei FQ; You PH; You S; Jiang YB; Zhang H; Cheng ZQ; Wang CR; Zeng YY
Int Immunopharmacol; 2023 Dec; 125(Pt A):111098. PubMed ID: 37925946
[TBL] [Abstract][Full Text] [Related]
17. A Comparison of Entecavir and Lamivudine for the Prophylaxis of Hepatitis B Virus Reactivation in Solid Tumor Patients Undergoing Systemic Cytotoxic Chemotherapy.
Chen WC; Cheng JS; Chiang PH; Tsay FW; Chan HH; Chang HW; Yu HC; Tsai WL; Lai KH; Hsu PI
PLoS One; 2015; 10(6):e0131545. PubMed ID: 26121480
[TBL] [Abstract][Full Text] [Related]
18. Association of hepatitis B virus DNA levels with overall survival for advanced hepatitis B virus-related hepatocellular carcinoma under immune checkpoint inhibitor therapy.
An M; Wang W; Zhang J; Till BG; Zhao L; Huang H; Yang Y; Li T; Han L; Zhang X; Qin P; Wang Y; Zhang M; Cui H; Gao Q; Wang Z
Cancer Immunol Immunother; 2023 Feb; 72(2):385-395. PubMed ID: 35907016
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis B virus reactivation after radiofrequency ablation or hepatic resection for HBV-related small hepatocellular carcinoma: a retrospective study.
Dan JQ; Zhang YJ; Huang JT; Chen MS; Gao HJ; Peng ZW; Xu L; Lau WY
Eur J Surg Oncol; 2013 Aug; 39(8):865-72. PubMed ID: 23597497
[TBL] [Abstract][Full Text] [Related]
20. Risk of HBV reactivation according to viral status and treatment intensity in patients with hepatocellular carcinoma.
Jang JW; Kwon JH; You CR; Kim JD; Woo HY; Bae SH; Choi JY; Yoon SK; Chung KW
Antivir Ther; 2011; 16(7):969-77. PubMed ID: 22024512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]